OOIR: Observatory of International Research

Papers

(The TQCC of Hematology-American Society of Hematology Education Program is 10. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-08-01 to 2025-08-01.)

Article	Citations
Inherited thrombophilia and recurrent miscarriage: is there a role for anticoagulation during pregnancy?	69
When should gene therapy be considered for transfusion-dependent β-thalassemia patients?	69
Neurological manifestations of MGUS	60
Anticoagulation at the end of life: whether, when, and how to treat	41
Your chemo is no good here: management of high-risk MCL	40
Hematopoietic cell transplantation for sickle cell disease: updates and future directions	39
Diagnosis and therapeutic decision-making for the neutropenic patient	36
On the horizon: upcoming new agents for the management of ITP	35
Labor and delivery: DIC, HELLP, preeclampsia	34
Mastocytosis demystified	31
Recognizing, defining, and managing CAR-T hematologic toxicities	30
Bispecific antibody therapies	30
Inpatient recognition and management of HLH	29
Has PD-1 blockade changed the standard of care for cHL?	28
Individualized patient care in nodular lymphocyte-predominant Hodgkin lymphoma	26
To consolidate or not to consolidate: the role of autologous stem cell transplantation in MCL	25
Logistics, risks, and benefits of automated red blood cell exchange for patients with sickle cell disease	25
T-cell–based therapies for treating relapsed or refractory mantle cell lymphoma	25
Double-refractory Hodgkin lymphoma: tackling relapse after brentuximab vedotin and checkpoint inhibitors	24
Mutation- and MRD-informed treatment decisions for the transplant-eligible AML patient	24
How to recognize and manage COVID-19-associated coagulopathy	23
Divergent paths: management of early relapsed follicular lymphoma	23
Fitness and frailty in myeloma	23
MGCS: where do we stand today?	23
BV and beyond: how to incorporate novel agents into PTCL management	23

Selecting initial therapy in CLL	22
New approaches to tackle cytopenic myelofibrosis	22
Chronic GVHD: review advances in prevention, novel endpoints, and targeted strategies	21
Hypoxia-inducible factor activators: a novel class of oral drugs for the treatment of anemia of chronic kidney disease	21
How to assess hemostasis in patients with severe liver disease	20
Increasing access to allogeneic hematopoietic cell transplant: an international perspective	20
Optimizing outcomes in secondary AML	20
Troubleshooting heparin resistance	20
Incidence, mechanism, and consequences of IV iron–induced hypophosphatemia	20
How to manage hemostasis in patients with liver disease during interventions	19
What is the optimal strategy for secondary prevention after venous thromboembolism in polycythemia vera?	19
Minimal intensity conditioning strategies for bone marrow failure: is it time for “preventative” transplants?	19
Advances in MGUS diagnosis, risk stratification, and management: introducing myeloma-defining genomic events	19
How to diagnose and manage antiphospholipid syndrome	19
Running interferon interference in treating PV/ET: meeting unmet needs	19
CHIP: is clonal hematopoiesis a surrogate for aging and other disease?	18
Consumptive coagulopathy in the ICU	18
Hemophilia gene therapy: ushering in a new treatment paradigm?	18
Mitigating, monitoring, and managing long-term chemotherapy- and radiation-induced cardiac toxicity	18
Incorporating novel agents into frontline treatment of Hodgkin lymphoma	18
Demystifying autoimmune HIT: what it is, when to test, and how to treat	17
Planning GvHD preemptive therapy: risk factors, biomarkers, and prognostic scores	17
Evaluating patients with autoimmune hemolytic anemia in the transfusion service and immunohematology reference laboratory: pretransfusion testing challenges and best transfusion-management strategies	17
Management of TKI-resistant chronic phase CML	17
Hematology 2022—what is complete HLA match in 2022?	17
The sum of the parts: what we can and cannot learn from comorbidity scores in allogeneic transplantation	17
Management of marginal zone lymphomas	16
How to manage bleeding disorders in aging patients needing surgery	16
Management of limited-stage Hodgkin lymphoma	16
What to use to treat AML: the role of emerging therapies	15
Managing therapy-associated neurotoxicity in children with ALL	14
Thrombosis questions from the inpatient wards	14
Special considerations in GI bleeding in VWD patients	14
Identifying Castleman disease from non-clonal inflammatory causes of generalized lymphadenopathy	14
Organ function indications and potential improvements following curative therapy for sickle cell disease	14
Atypical CML: diagnosis and treatment	14
Approaches to management of HIT in complex scenarios, including cardiac surgery	14
Targeting hardship: poverty as a modifiable risk factor in childhood leukemia and lymphoma treatment	14
Lower risk but high risk	13
Transplant in AML with measurable residual disease: proceed or defer?	13
Infectious complications and vaccines	13
Treatment of VTE in the thrombocytopenic cancer patient	13
When does a PNH clone have clinical significance?	13
Alloimmunization and hyperhemolysis in sickle cell disease	13
CNS prophylaxis in aggressive B-cell lymphoma	13
Adolescents and young adults (AYAs) vs pediatric patients: survival, risks, and barriers to enrollment	13
Should older patients with low weight and CKD receive full-dose DOACs for treatment of acute proximal DVT?	13
Nontransplant treatment approaches for myeloid neoplasm with mutated TP53	13
The evolving frontline management of CLL: are triplets better than doublets? How will we find out?	13
Relapsed disease: off-the-shelf immunotherapies vs customized engineered products	13

Pegylated interferon: the who, why, and how	13
What makes a pediatric or young adult patient an appropriate transplant candidate?	12
Thrombocytopenia in pregnancy	12
What is the role of up-front autologous stem cell transplantation in mantle cell lymphoma?	12
Pyruvate kinase activators: targeting red cell metabolism in sickle cell disease	12
Cytoreduction for ET and PV: who, what, when, and how?	12
What is the ideal approach—doublet, triplet, or quadruplet(s)?	12
How to evaluate the patient with a suspected mast cell disorder and how/when to manage symptoms	12
Managing pregnancy in patients with sickle cell disease from a transfusion perspective	11
Ph− ALL: immunotherapy in upfront treatment	11
Novel therapies and combinations in CLL refractory to BTK inhibitors and venetoclax	11
Clinical manifestations of telomere biology disorders in adults	11
Next-generation therapy for lower-risk MDS	11
β-Thalassemia: evolving treatment options beyond transfusion and iron chelation	11
MRD in adult Ph/BCR-ABL-negative ALL: how best to eradicate?	10
Novel therapies upon failure of HMA plus venetoclax	10
Stem cell transplantation for ALL: you've always got a donor, why not always use it?	10
Porphyria cutanea tarda: a unique iron-related disorder	10
Frontline treatment in CLL: the case for time-limited treatment	10
Should we use bisphosphonates to treat bone complications in sickle cell disease?	10
What else do I need to worry about when treating graft-versus-host disease?	10
Thrombocytopenia and liver disease: pathophysiology and periprocedural management	10
Sequencing bispecific antibodies and CAR T cells for FL	10
Whom should we treat with novel agents? Specific indications for specific and challenging populations	10
The role of stem cell transplant (auto and allo) in PTCL and CTCL	10
Approach to the patient with suspected hypereosinophilic syndrome	10
Managing side effects: guidance for use of immunotherapies in multiple myeloma	10